Inscription Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Inscription Capital's REGN Position: Q2 2026 in Review
Inscription Capital increased its Regeneron Pharmaceuticals (REGN) stake by 99% in Q2 2026, buying an estimated $240K and bringing the position to 709 shares worth $442K. The position accounts for 0.04% of the portfolio, ranked #429.
Inscription Capital first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Inscription Capital held 709 shares of Regeneron Pharmaceuticals worth $442K as of Q2 2026.
- Inscription Capital bought 352 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $240K.
- Regeneron Pharmaceuticals made up 0.04% of Inscription Capital's portfolio in Q2 2026, its #429 holding.
- Inscription Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.